Thursday’s trading saw notable activity across stocks, particularly in the mega-cap and large-cap categories. Some stocks have seen significant gains after earnings announcements, while others have faced significant declines due to a variety of factors. Here are some of the companies making the most important moves in the market today, from the largest companies by market capitalization to smaller companies making waves.
Mega-Cap Movers (market capitalization over $200 billion):
Accenture Corporation (NYSE:): Accenture reports first quarter 2025 results. +7.48% Nvidia Inc. (NASDAQ:): +3.01% oracle company (New York Stock Exchange:): +3.15%
Movement of large stocks (market capitalization between $10 billion and $200 billion):
Darden Restaurants (NYSE:): Darden Restaurants reports second quarter 2025 results. Declare quarterly dividends. Updated financial outlook for fiscal year 2025. +15.46% Lamb Weston Holdings Co., Ltd. (NYSE:): Lamb Weston reports lower second-quarter profit and lowers outlook. -20.85% micron tech (MU): Micron Technology (NASDAQ:), Inc. reports first quarter 2025 results. -16.21% vertex farm (NASDAQ:): Vertex reports mixed results in Phase 2 pain study. -11.95% Cintas Corporation (NASDAQ:): Cintas shares rise slightly after second-quarter profit beats; full-year outlook raised. -9.09% Summit Therapeutics PLC (NASDAQ:): +8.33%MSTU (MSTU): -8.19%FBTC NYSE (FBTC): -1.81%
Mid-cap equity transfer companies (market capitalization $2 billion to $10 billion):
Quantum (NASDAQ:) Computing OTC (QUBT): -43.61% Righetti Computing Inc (NASDAQ:): -29.38%DPCM Capital (QBTS): -28.91%AltC Acquisition (OKLO): +14.91% C3I Co., Ltd. (NYSE:): -11.26%BITX (BITX): -4.35%MSTZ (MSTZ): +9.32% Oaktree Acquisition Corporation (New York Stock Exchange:): -9.7% Soundhound AI (NASDAQ:): -9.23% joby aviation (New York Stock Exchange:): -7.35%
Small-cap movers (market cap $300 million to $2 billion):
Membership Collective Group (SHCO): +58.25% Omeros company (NASDAQ:): Omeros reports survival benefit with narsoplimab in TA-TMA. +35.39% Prothena Corporation PLC (PRTA): Roche’s Phase IIb trial of placinezumab failed to meet primary endpoint, but suggests potential clinical benefit in early Parkinson’s disease. +40.67%Centricus acquisition (ARQQ): -29.73% Kango Co., Ltd. (NYSE:): -27.13%Tuscan Holdings Corp (MVST): +28.26%UVIX (UVIX): +13.32%Flame Acquisition (SOC): +16.22%CMI Acquisition LLC (SKYT): -16.62%Innodata Isogen (INOD) : +15.53%
Join Investing Pro for real-time market-moving news.
This article was generated with the help of AI and reviewed by an editor. Please see our Terms of Use for more information.
